Full Length Research Paper
References
|
Arruzabala ML, Molina V, Mas R, Carbajal D, Marrero D, Gonzalez V, Rodriguez E (2006). Effect of coconut oil on tesetosterone induced prostastic hyperplasia in SD rats. J. Pharm. Pharmcol. 59(7):995-999. |
|
|
Babu SV, Veeresh B, Patil AA, Warke YB (2010). Lauric acid and myristic acids prevents testosterone induced prostatic hyperplasia in rats. Eur. J. Pharmcol. 626(2):262-265. |
|
|
Bartsch G, Rittmaster RS, Klocker H (2000). Dihydrotestosterone and 5- alpha reductase inhibition in human benign prostatic hyperplasia. Eur. Urol. 37(4):367-368. |
|
|
Bisson JF, Hidalgo S, Rozan P, Messaoudi M (2007). Therapeutic effect of ACTICOA powder, a cocoa polyphenolic extract on experimentally induced prostate hyperplasia in Wistar-Unilever rats. J. Med. Food 10(4):628-635. |
|
|
Carson C, Rittmaster R (2003). The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61(4):2-7. |
|
|
Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Lzumi T, Abiko Y (1982). Alphaadrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J. Urol. 128(4):836-839. |
|
|
Gasco M, Villegas L, Yucra S, Rubio J, Gonzales CF (2007). Dose-response effect of Red Maca (Lepidium myenii) on benign prostatic hyperplasia induced by testosterone enanthate. Phytomedicine 14(7):460-464. |
|
|
Girman CJ, Jacobsen SJ, Guess HA, Oesterling JE, Chute CG, Panser LA, Lieber MM (1995). Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J. Urol. 153(5):1510-1515. |
|
|
Griffiths K, Denis LJ (2000). Exploitable mechanisms for the blockade of androgenic action. Prostate 10(S10):43-51. |
|
|
Jang H, Ha US, Kim SJ, Yoon BI, Han DS, Yuk SM, Kim SW (2010). Anthocyanin extracted from black soybean reduces prostate weight and promotes apoptosis in the prostatic hyperplasia-induced rat model. J. Agric. Food Chem. 58(24):12686-12691. |
|
|
Lepor H (2000). The pathophysiology of lower urinary tract symptoms in the aging male population. In: Lepor H, editor. Prostatic diseases. Philadelphia, PA:WB Saunders. pp. 163-196. |
|
|
Liang T, Liao S (1992). Inhibition of steroid 5 α-reductase by specific alpha1-adernoceptors subtype in humans car aliphatic unsaturated fatty acids. Biochem. J. 285:557-562. |
|
|
McNeal JG (1983). The prostate gland: morphology and pathobiology. Monogr. Urol. 4:3-33. |
|
|
Michel MC, Taguchi K, Schfers RS, Williams TJ, Clarke D, E, Ford AP (1998). alpha1-adernoceptors subtype in humans cardiovascular and urogenital system. Adv. Pharmcol. 42:394-398. |
|
|
Niu YJ, Ma TX, Zhang J, Xu Y, Han RF, Sun G (2003). Androgen and prostatic stroma. Asian J. Androl. 5:19-26. |
|
|
Pais P (2010). Potency of a novel saw palmetto extract, SPET-85, for inhibition of 5alpha-reductase II. Adv. Ther. 27:555-563. |
|
|
Patel AK, Chapple CR (2008). Benign prostatic hyperplasia: Treatment in primary health care. BMJ 333:535-539. |
|
|
Roehrborn CG (2011). Male lower urinary tract symptoms (LUTS) and benignprostatic hyperplasia (BPH). Med. Clin. North Am. 95(1):87-100. |
|
|
Span PN, Völler MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, Kirby RS (1999). Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J. Urol. 161(1):332-337. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
